ScalmiBio

ScalmiBio Minimizes Side Effects of Antibody Therapies in Oncology and Immuno-OncologyScalmiBio’s proprietary SHIELD platform technology converts therapeutic antibodies into prodrugs that are specifically activated within tumors. Adverse events associated with the presence of specific targets in normal tissues limit the dosage and efficacy of antibody therapies and hinder the evaluation of potential targets in clinical trials. SHIELD technology restricts the activity of antibody therapies to the tumor microenvironment, minimizing side effects, enabling higher therapeutic doses, and allowing broader application of multi-target combination therapies.